Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;86(3):223-229.
doi: 10.1016/j.eururo.2024.04.037. Epub 2024 May 20.

Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial

Affiliations

Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial

Andreas Josefsson et al. Eur Urol. 2024 Sep.

Abstract

Background and objective: We investigated whether adding 4Kscore as a reflex test to prostate-specific antigen (PSA) could improve the screening algorithm for prostate cancer (PC).

Methods: In the GÖTEBORG-2 PC screening trial, 38 000men (50-60 yr) were invited to PSA testing and, if elevated, followed by magnetic resonance imaging (MRI). For 571 men with PSA ≥3.0 ng/ml and evaluable outcomes, 4Kscore was calculated. The performance using a prespecified 4Kscore cutoff of 7.5% was evaluated.

Key findings and limitations: The area under the curve for 4Kscore to identify intermediate- and high-risk PC was 0.84 (95% confidence interval 0.79-0.89), and the positive predictive value, and negative predictive value were 15% (0.12-0.20) and 99% (97-100%), respectively. Of the 54 men diagnosed with intermediate- or high-grade PC, two had a 4Kscore cutoff below 7.5%, both with organ-confined intermediate-risk PC. Per 1000 men with elevated PSA, adding 4Kscore would have resulted in avoidance of MRI for 408 (41%) men, biopsies for 95 (28% reduction) men, and diagnosis of 23 low-grade cancers (23% reduction) while delaying the diagnosis of four men with intermediate-grade cancers (4%).

Conclusions and clinical implications: Including 4Kscore as a reflex test for men with elevated PSA reduces the need for MRI and biopsy markedly, and results in less overdiagnosis of low-grade PC at the cost of delaying the diagnosis of intermediate-grade PC in a few men. These results add further evidence for including new blood-based biomarkers in addition to PSA to improve the harm and benefit ratio of PC screening and reduce the need for resource-demanding MRI and biopsies.

Keywords: 4Kscore; GOTEBORG-2 study; Magnetic resonance imaging; Prostate cancer; Prostate-specific antigen; Screening.

PubMed Disclaimer

Figures

Fig. 1 –
Fig. 1 –
Study flow. G2 study = GÖTEBORG-2 randomized screening study; G2B = biomarker study within G2 study; ISUP = International Society of Urological Pathology; MRI = magnetic resonance imaging; PSA = prostate-specific antigen.
Fig. 2 –
Fig. 2 –
Box-dot plots of 4Kscore distribution by MRI and biopsy outcome. MRI = magnetic resonance imaging; ISUP = International Society of Urological Pathology; MRI = magnetic resonance imaging.
Fig. 3 –
Fig. 3 –
Sensitivity, specificity, PPV, and NPV by different cutoffs of 4Kscore for the diagnosis of intermediate- to high-grade prostate cancer (ISUP ≥2). ISUP = International Society of Urological Pathology; NPV = negative predictive value; PPV = positive predictive value.

References

    1. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–8. - PubMed
    1. Schroder FH, Hugosson J, Carlsson S, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012;62:745–52. - PubMed
    1. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725–32. - PMC - PubMed
    1. Egevad L, Delahunt B, Srigley JR, Samaratunga H. International Society of Urological Pathology (ISUP) grading of prostate cancer–an ISUP consensus on contemporary grading. APMIS 2016;124:433–5. - PubMed
    1. Kasivisvanathan V, Stabile A, Neves JB, et al. Magnetic resonance imaging-targeted biopsy versus systematic biopsy in the detection of prostate cancer: a systematic review and meta-analysis. Eur Urol 2019;76:284–303. - PubMed